- Report
- November 2020
- 260 Pages
Global
From €1338EUR$1,375USD£1,146GBP
€2676EUR$2,750USD£2,292GBP
- Report
- December 2019
- 165 Pages
Global
From €1338EUR$1,375USD£1,146GBP
€2676EUR$2,750USD£2,292GBP
- Report
- November 2021
- 245 Pages
Global
From €4816EUR$4,950USD£4,126GBP
- Drug Pipelines
- September 2022
- 280 Pages
Global
From €2335EUR$2,400USD£2,000GBP
- Report
- March 2023
- 130 Pages
Global
From €5789EUR$5,950USD£4,959GBP
- Report
- May 2020
- 51 Pages
Global
From €4816EUR$4,950USD£4,126GBP
- Report
- April 2023
- 115 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2022
- 60 Pages
Global
From €3843EUR$3,950USD£3,292GBP
- Report
- January 2022
- 60 Pages
Global
From €3843EUR$3,950USD£3,292GBP
- Report
- January 2022
- 60 Pages
Global
From €3843EUR$3,950USD£3,292GBP
- Report
- January 2022
- 60 Pages
Global
From €3843EUR$3,950USD£3,292GBP
- Report
- February 2020
- 101 Pages
Global
From €2919EUR$3,000USD£2,501GBP
- Drug Pipelines
- January 2019
- 60 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- October 2021
- 100 Pages
Global
From €4378EUR$4,500USD£3,751GBP
- Report
- September 2018
Global
From €4378EUR$4,500USD£3,751GBP
- Report
- November 2020
- 90 Pages
Middle East, Africa
From €2043EUR$2,100USD£1,750GBP
€2919EUR$3,000USD£2,501GBP
- Report
- November 2020
- 140 Pages
From €2043EUR$2,100USD£1,750GBP
€2919EUR$3,000USD£2,501GBP
Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more